Pulmonx Shares Surge on Leadership Shakeup and Upbeat Forecast

Pulmonx Corp witnessed a dramatic single-day rally, with its stock price soaring more than 26% following significant corporate developments. The surge was fueled by a major leadership overhaul and a quarterly revenue projection that surpassed market expectations.

Market Reaction and Trading Activity

The financial markets responded immediately to the corporate announcements made on October 27. Starting the session at $1.56, Pulmonx shares experienced a powerful upward move, closing at $1.98 to register a 26.9% gain within just twenty-four hours. This substantial advance represents a notable shift for the equity, which has previously traded within a range of $1.47 to $9.37.

Executive Leadership Reshuffle

The medical technology company is implementing transformative changes to its executive team. Effective immediately, Glen French has resumed the roles of President and Chief Executive Officer. In a complementary move, Derrick Sung will assume the combined responsibilities of Chief Operating Officer and Chief Financial Officer beginning in early November.

Both executives bring substantial institutional knowledge to their positions. French previously led Pulmonx from 2014 through 2024, while Sung served as CFO until October 2023. The compensation packages for the returning leaders include significant equity awards structured with performance-based vesting criteria. Notably, a portion of these incentives is directly tied to the company’s stock surpassing the $4 threshold.

Should investors sell immediately? Or is it worth buying Pulmonx Corp?

Financial Performance Outlook

Beyond the management changes, Pulmonx delivered an encouraging preliminary revenue estimate for the third quarter of 2025. The company anticipates reporting approximately $21.5 million in revenue, slightly exceeding some analyst projections that had centered around $20.78 million.

Investors should note an adjustment to the financial calendar. The definitive earnings release and accompanying conference call have been rescheduled from late October to November 12, when comprehensive financial details will be provided.

Analyst Perspective and Future Potential

Market observers continue to identify substantial upside potential for Pulmonx shares. The consensus price target among analysts stands at $6.81, representing more than triple the current trading level. The combination of seasoned leadership returning to helm the company and solid fundamental performance could establish a foundation for continued positive momentum.